Richard B. Moss, M.D.
Dr. Moss is professor of Pediatrics at Stanford University School of medicine and chief, pediatric pulmonology and allergy with over 150 scientific publications. He is the chair of the protocol review committee for the Cystic Fibrosis Therapeutics Development Network (TDN). Dr. Moss’s honors include The Best Doctors in America, America’s Top Pediatricians - Pulmonology and Professional of the Year by the Cystic Fibrosis Foundation (CFF). His research involves the immunoregulation of inflammation in cystic fibrosis and he has been involved in numerous CF clinical trials. One of his research interests is aerosol gene therapy for in vivo correction of genetic lung disease and new treatments for CF complications such as diabetes and osteoporosis.

Thomas Hofmann , M.D./Ph.D.,
Dr.Hofmann has extensive industry and clinical experience in developing inhalable medicines to treat lung infectious diseases and asthma. He was VP of New Product Development at Discovery Labs, a leader in lung surfactants therapeutics. He was also Senior Medical Director at Corus Pharma (now Gilead) where he played a pivotal role in developing inhalable antibiotics aztreonam (CaystonTM) for cystric fibrosis and other lung infections. Prior to Corus, he served as Medical Director at Pulmopharm . Dr. Hofmann also is an expert in aerosol delivery of medications and has served as scientific advisor to several medical device companies. He received his medical degree at Justus-Liebig-Universität Giessen University and post-doctoral training at the University of North Carolina at Chapel Hill School of Medicine focusing on cystic fibrosis.

Alan H Cohen, MD, FAAP, FCCP
Dr Cohen is a board certified Pediatric Pulmonologist and currently the Vice President, Clinical Development and Medical Affairs, Pulmonary, at MAP Pharmaceuticals, in Palo Alto, CA. He also holds an appointment as adjunct clinical faculty at Stanford University School of Medicine – in the Dept of Pediatric Pulmonology and Allergy. He is the author of over 100 peer reviewed articles, abstracts, platform presentations and book chapters in his areas of interest and expertise, including Cystic Fibrosis, Lung Transplantation, Infectious Disease and respiratory pathogens – such as RSV, influenza and molds. He was formerly the Senior Director of Medical Affairs at Medimmune, Inc – involved in drug discovery of monoclonal antibodies and vaccines. He has held faculty appointments at a number of prestigious centers of learning and healthcare including the Johns Hopkins School of Medicine, Morehouse School of Medicine, Washington University School of Medicine, as well as the University of Colorado / National Jewish Center for Immunology and Respiratory Diseases.

Lisa Saiman, M.D.
Clinical Consultant
Dr. Saiman is Professor of Clinical Pediatrics at Columbia University and Director of the CF Referral Center for Susceptibility and Synergy Studies. She has over 140 publications in infectious disease and cystic fibrosis.
Dr. Saiman is a member of the CF Foundation Clinical Research Committee and Principal investigator on numerous CF clinical trials including demonstrating efficacy of Azithromycin to treat CF lung infections.

Bruce K. Rubin, M.Engr., M.D., MBA
Dr.Rubin is Professor & Vice Chair of Pediatrics, Professor of Physiology & Pharmacology, & Professor of Biomedical Engineering at Wake Forest University with over 150 scientific publications. He is a Fellow of the Royal College of Physicians in Canada, the American College of Chest Physicians, and a member of the American Pediatric Association. He is the President of the International Congress of Pediatric Pulmonology. Dr. Rubin received the Alfred Soffer Award for Editorial Excellence 2004. He is listed in Who’s Who in Science and Engineering, Who’s Who in the United States, and The Best Doctors in America. Dr Rubin’s research is regulation of mucus clearance in health and disease and aerosol delivery of medications. He directs the only comprehensive Mucus Clearance Disorder’s clinic in the United States for the assessment & treatment of adults and children with difficulty to manage mucus problems.